Pfizer (NYSE:PFE) Stock Price Down 1.6% – Should You Sell?

by · The Cerbat Gem

Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded down 1.6% on Tuesday . The stock traded as low as $25.13 and last traded at $25.3550. 43,360,166 shares changed hands during mid-day trading, a decline of 15% from the average session volume of 51,228,027 shares. The stock had previously closed at $25.77.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup started coverage on Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target for the company. Bank of America lifted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.39.

View Our Latest Report on PFE

Pfizer Stock Down 1.6%

The company has a market cap of $144.16 billion, a PE ratio of 14.74 and a beta of 0.46. The stock has a 50-day moving average of $25.21 and a 200-day moving average of $24.71. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 7th were given a dividend of $0.43 per share. The ex-dividend date was Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s payout ratio is presently 100.00%.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently made changes to their positions in PFE. Vanguard Group Inc. raised its position in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares in the last quarter. State Street Corp raised its holdings in shares of Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after buying an additional 2,786,098 shares in the last quarter. Geode Capital Management LLC lifted its position in Pfizer by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after buying an additional 1,820,634 shares during the last quarter. Norges Bank purchased a new stake in Pfizer in the second quarter worth approximately $2,270,157,000. Finally, Northern Trust Corp grew its position in Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after acquiring an additional 869,175 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More